TLSA vs. ESPR, SLRN, FBLG, CTNM, TERN, BMEA, ORGO, VRCA, AMRN, and PGEN
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Esperion Therapeutics (ESPR), Acelyrin (SLRN), FibroBiologics (FBLG), Contineum Therapeutics (CTNM), Terns Pharmaceuticals (TERN), Biomea Fusion (BMEA), Organogenesis (ORGO), Verrica Pharmaceuticals (VRCA), Amarin (AMRN), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Esperion Therapeutics (NASDAQ:ESPR) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.
Esperion Therapeutics received 506 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. Likewise, 69.92% of users gave Esperion Therapeutics an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote.
Tiziana Life Sciences has lower revenue, but higher earnings than Esperion Therapeutics.
Esperion Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
In the previous week, Esperion Therapeutics had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for Esperion Therapeutics and 3 mentions for Tiziana Life Sciences. Esperion Therapeutics' average media sentiment score of 0.97 beat Tiziana Life Sciences' score of 0.73 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.
Esperion Therapeutics currently has a consensus target price of $9.33, suggesting a potential upside of 332.10%. Given Tiziana Life Sciences' higher probable upside, equities research analysts clearly believe Esperion Therapeutics is more favorable than Tiziana Life Sciences.
47.4% of Esperion Therapeutics shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Tiziana Life Sciences has a net margin of 0.00% compared to Tiziana Life Sciences' net margin of -37.65%.
Summary
Esperion Therapeutics beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
